Acurx Pharmaceuticals Stock (NASDAQ:ACXP)
Previous Close
$1.86
52W Range
$1.52 - $5.28
50D Avg
$2.02
200D Avg
$2.34
Market Cap
$30.05M
Avg Vol (3M)
$48.71K
Beta
-1.73
Div Yield
-
ACXP Company Profile
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
ACXP Performance
Peer Comparison
Ticker | Company |
---|---|
ENOB | Renovaro Biosciences Inc. |
PMVP | PMV Pharmaceuticals, Inc. |
MNPR | Monopar Therapeutics Inc. |
MLYS | Mineralys Therapeutics, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
ACRV | Acrivon Therapeutics, Inc. Common Stock |
ANTX | AN2 Therapeutics, Inc. |
RZLT | Rezolute, Inc. |
CADL | Candel Therapeutics, Inc. |
SILO | Silo Pharma, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
ADAG | Adagene Inc. |
LUMO | Lumos Pharma, Inc. |